Metropolis Healthcare Limited — PPTs, 04-11-2025: Investor Presentation

Metropolis Healthcare delivered strong Q2FY26 results! Group revenue jumped 23% YoY to ₹429 Cr, with PAT up 13% to ₹53 Cr. Organic business also showed robust 12% revenue growth. EBITDA margins improved to 25.4% for the group, driven by efficiency and integrating acquisitions like Core Diagnostics. Growth was primarily from preventive health (TruHealth) and specialty tests, even with fewer seasonal illnesses.

The 'Metropolis 3.0' strategy targets mid-teen revenue CAGR and aims for pre-COVID margins, focusing on market share expansion, specialized testing, and new areas like radiology and genomics. Digital transformation, including AI-powered platforms, is key to boosting productivity and customer experience.

Network expanded significantly, adding 4 labs and 134 service centers in Q2FY26, now serving ~750 towns. Recent acquisitions are integrating well. New AI-verified tests like prostate biopsy and AI Karyotyping were launched. Organic TruHealth revenue surged 21% YoY.

Management is committed to being the fastest-growing national diagnostics chain, leveraging scientific innovation and network reach. A dividend of ₹4 per share was approved.